Incidensen i forbindelse med ikke- primær PCI var for UA/ NSTEMI 1% versus 0, 3% (fondaparinux versus enoxaparin), og ved primær PCI hos STEMI- patienter var incidensen 1, 2% versus 0% (fondaparinux versus kontrolgruppe).
Incidences in non-primary PCI in UA/ NSTEMI were 1.0% vs 0.3% (fondaparinux vs. enoxaparin) and in primary PCI in STEMI were 1.2% vs 0% (fondaparinux vs. control).